Brief: Samsung Biologics & STCube Enter Development & Manufacturing Agreement​ For ‍STT-003 Antibody​

STCube

02/03/2020 19:04

March 2 (Reuters) - Samsung Biologics Co:
    * SAMSUNG BIOLOGICS CO LTD -  CO & STCUBE ANNOUNCED A
STRATEGIC
DEVELOPMENT AND MANUFACTURING SERVICE AGREEMENT FOR STT-003
ANTIBODY
    * SAMSUNG BIOLOGICS CO LTD - CO TO OFFER CELL LINE
DEVELOPMENT,
PROCESS DEVELOPMENT, OTHERS TO IND SUBMISSION FOR STT-003
ANTIBODY
    * SAMSUNG BIOLOGICS CO LTD - STCUBE IS PLANNING TO SUBMIT AN
IND
ON ITS STT-003 ANTIBODY IN 2021

Source text for Eikon:  ID:nPn2DPKmFa 
Further company coverage:  052020.KQ 

 ((Reuters.briefs@thomsonreuters.com;))